Document is current
Any future updates will be listed below
-
Authors
Okabe, Seiichi
Moriyama, Mitsuru
Gotoh, Akihiko
-
Funding
Funding for this research was provided by:
The Japanese Ministry of Education, Culture, Sports, Science, and Technology (20K07644)
- License Information
-
More Information
Article History
Received: 3 March 2024
Accepted: 24 April 2024
First Online: 7 May 2024
Declarations
:
: A.G. received research funding from Eisai Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Nippon Shinyaku Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; MSD K.K.; Otsuka Pharmaceutical Co., Ltd.; Sumitomo Pharma Co., Ltd.; Nippon Shinyaku Co., Ltd.; Bayer Yakuhin, Ltd.; Daiichi Sankyo Co., Ltd.; and Nihon Pharmaceutical Co., Ltd. A.G. received honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., and Sanofi K.K.. A.G. received consulting fees from PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd.; and Alexion Pharmaceuticals, Inc. In addition, A.G. participated in the data safety monitoring board or advisory board of PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., and Alexion Pharmaceuticals, Inc. S.O. and M.M. report no conflicts of interest.
: Not applicable.
: Not applicable.
